Latest Production News

Genesis Minerals delivered record gold production and a robust cash build in December 2025, while accelerating development at its Tower Hill project ahead of schedule.

Biotron Limited has completed the acquisition of Sedarex Limited alongside a $2.5 million capital raising, while its lead Hepatitis B drug candidate BIT-HBV001 shows promising preclinical results outperforming current treatments.

Genesis Minerals has restructured its executive team, appointing Raleigh Finlayson as Executive Chair and promoting Matthew Nixon to CEO, positioning the company for a significant growth phase.

CurveBeam AI reported steady progress in Q2 FY26 with five new device purchase orders, a $4 million milestone payment pending receipt, and key regulatory submissions underway in the US and China.

CurveBeam AI reported steady device orders alongside a $4 million milestone payment from its China commercialisation deal, while progressing FDA clearance and robotic surgery system validation.

Arafura Rare Earths has raised A$481 million in equity funding and secured key government backing, advancing its Nolans Project towards a final investment decision in 2026.

INOVIQ Limited has completed a $10.2 million capital raise to accelerate development of its exosome-based ovarian cancer screening test and CAR-exosome therapeutics, alongside key leadership appointments and promising preclinical results.

Felix Gold Limited reports significant gold assay results from its NW Array prospect in Alaska, confirming extensive gold mineralisation alongside high-grade antimony. This comes as gold prices soar past US$5,000/oz, highlighting the project's strategic potential near Kinross Gold's Fort Knox mill.

Prairie Lithium has secured a 10-year binding export agreement with South Korea’s Hydro Lithium and progressed key construction milestones at its Saskatchewan project, positioning itself as a rising player in North America’s lithium sector.

Barton Gold Holdings has completed significant drilling upgrades and advanced feasibility studies across its South Australian projects, raising $15 million to support a targeted production restart by the end of 2026.

dorsaVi reports strong US commercial growth with over 100 new physical therapy sites and a 50% rise in cash receipts, alongside a strategic leadership change and breakthrough neuromorphic technology acquisition.

Acrux Limited reports solid revenue growth and increased cash reserves in the December quarter, driven by expanding its topical generics portfolio in the US and strategic moves into female Hormone Replacement Therapy.